Physician profile
Jonathan Finegold
NPI 1336206846
$4,107.60
in general payments reported to CMS, 2019-2025
13 companies · $373 in 2025
The $373 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $27.56 · 2021: $475 · 2022: $569 · 2023: $1,459 · 2024: $1,204 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,036.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,075.17 | 2022-2024 | Zeposia |
| Abbvie INC. | $976.73 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $572.77 | 2022-2024 | Xifaxan, Trulance |
| Celgene Corporation | $308.40 | 2022-2024 | Zeposia |
| Braintree Laboratories, INC. | $300.52 | 2021-2023 | Sutab |
| Celltrion USA INC. | $257.96 | 2024 | Zymfentra |
| Ferring Pharmaceuticals INC. | $224.21 | 2021-2023 | Rebyota |
| Micro-Tech Endoscopy USA, INC. | $129.94 | 2021-2024 | Clips (Need Marketed Device Name), Lesion Hunter, Needles (Needmarketed Name of Devices) |
| Takeda Pharmaceuticals U.S.A., INC. | $100.76 | 2021-2022 | |
| Amgen INC. | $81.39 | 2023 | Amjevita, Avsola |
| Qol Medical, LLC | $29.72 | 2022 | |
| Janssen Biotech, INC. | $27.56 | 2020 | |
| Intercept Pharmaceuticals, INC. | $22.47 | 2023 | Ocaliva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Finegold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.